Mubadala Investment Company and Novo Holdings A/S Invest € 250 million in Evotec SE
HAMBURG, GERMANY / ACCESSWIRE / October 12, 2020 / Evotec SE (FSE:EVT)(OTC PINK:EVTCY)(MDAX/TecDAX, ISIN: DE0005664809, WKN 566480) today announced that it resolved on a capital increase from its authorised capital without pre-emptive rights against cash. Evotec will issue a total of 11,478,315 new shares to Mubadala Investment Company and Novo Holdings A/S.
In this private capital increase, Mubadala Investment Company will invest € 200 million to subscribe 9,182,652 Evotec shares at a share price of € 21.7802 per share representing approx.
The placement was made at
While maintaining the business outlook 2020 unchanged, Evotec will be using the proceeds from the capital increase to pursue its unique strategy to become the global leading platform company for the modality-agnostic development of innovative first-in-class and best-in-class therapeutic approaches resulting in a very large co-owned pipeline.
CONTACT:
Dr Werner Lanthaler
Chief Executive Officer
Evotec SE
Manfred Eigen Campus
Essener Bogen 7
22419 Hamburg, Germany
Phone: +49.(0)40.560 81-242
Email: werner.lanthaler@evotec.com
SOURCE: Evotec AG via EQS Newswire
View source version on accesswire.com:
https://www.accesswire.com/610212/Mubadala-Investment-Company-and-Novo-Holdings-AS-Invest-250-million-in-Evotec-SE